fda compounding semaglutide warning september 2025 New project announcement: HHS‑OIG is taking a closer look at FDA's oversight of compounded GLP‑1 drugs. Although shortages ended in 2025, some facilities may still be producing these drugs at scale. Our FDA issued 25 warning letters

10.1016/j.kint.2017.05.034 Kidney Int

The hormonal environment is shifting, but the downstream effects on fat and muscle tissue take longer to manifest visibly

Common ones include nausea, digestive changes, fatigue, or headaches especially during the initial titration phase

Frequently Asked Questions References [1] [2] National Library of Medicine, Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing, Gwyer, D., Wragg, N., Wilson, S., 2017 [3] [5] National Library of Medicine, Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review, Vasireddi, N., Hahamyan, H., Salata, M., Karns, M., Calcei, J., Voos, J., Apostolakos, J., July 2025 [4] National Library of Medicine, Modulatory effects of BPC 157 on vasomotor tone and the activation of Src-Caveolin-1-endothelial nitric oxide synthase pathway, Hsieh, M., Lee, C., Cheh, H., Chang, G, Huang, H., Lin, Y., Pang, J., October, 2020